Suvorexant Patent Expiration
Suvorexant is Used for promoting sleep and treating insomnia. It was first introduced by Merck Sharp And Dohme Corp
Suvorexant Patents
Given below is the list of patents protecting Suvorexant, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Belsomra | US10098892 | Solid dosage formulations of an orexin receptor antagonist | May 29, 2033 | Merck Sharp Dohme |
| Belsomra | US11980623 | Solid dosage formulations of an orexin receptor antagonist | May 29, 2033 | Merck Sharp Dohme |
| Belsomra | US12599610 | Solid Dosage Formulations Of An Orexin Receptor Antagonist | May 29, 2033 | Merck Sharp Dohme |
| Belsomra | US7951797 | Substituted diazepan orexin receptor antagonists | Nov 20, 2029 | Merck Sharp Dohme |
Suvorexant's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Suvorexant:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of Suvorexant (MK-4305) for the Treatment of Insomnia Disorder in Participants With Opioid Use Disorder (MK-4305-098) | Merck Sharp & Dohme LLC | NA |
RECRUITING
(Sep 1, 2026)
| PHASE3 |
| Suvorexant for Alcohol Use Disorder (AUD): Neural Mechanisms | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | NA |
RECRUITING
(Aug 6, 2026)
| PHASE1, PHASE2 |
| Sleep Trial to Prevent Alzheimer's Disease | University of Minnesota | NA |
RECRUITING
(Jul 1, 2026)
| PHASE2 |
| Suvorexant for Treatment of AUD and PTSD | Pharmacotherapies for Alcohol and Substance Use Disorders Alliance | NA |
RECRUITING
(Jun 1, 2026)
| PHASE2 |
| Trial of Suvorexant for Sleep in Children With Autism | Stanford University | NA |
RECRUITING
(Mar 1, 2026)
| PHASE2 |